Antimicrobial Prophylaxis Redosing Reduces Surgical Site Infection Risk in Prolonged Duration Surgery Irrespective of Its Timing.


Journal

World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 12 7 2019
medline: 29 1 2020
entrez: 12 7 2019
Statut: ppublish

Résumé

Long-duration surgery requires repeated administration of antimicrobial prophylaxis (amp). Amp "redosing" reduces incidence of surgical site infections (SSI) but is frequently omitted. Clinical relevance of redosing timing needs to be investigated. Here, we evaluated the effects of compliance with amp redosing and its timing on SSI incidence in prolonged duration surgery. Data from >9000 patients undergoing visceral, trauma, or vascular surgery with elective or emergency treatment in two tertiary referral Swiss hospitals were analyzed. All patients had to receive amp preoperatively and redosing, if indicated. Antibiotics used were cefuroxime (1.5 or 3 g, if weight >80 kg), or cefuroxime and metronidazole (1.5 and 0.5 g, or 3 and 1 g doses, if weight >80 kg). Alternatively, in cases of known or suspected allergies, vancomycin (1 g), gentamicin (4 mg/Kg), and metronidazole or clindamycin (300 mg) with or without ciprofloxacin (400 mg) were used. Association of defined parameters, including wound class, ASA scores, and duration of operation, with SSI incidence was explored. In the whole cohort, SSI incidence significantly correlated with duration of surgery (ρ = 0.73, p = 0.031). In 593 patients undergoing >240 min long interventions, duration of surgery was the only parameter significantly (p < 0.001) associated with increased SSI risk, whereas wound class, ASA scores, treatment areas, and emergency versus elective hospital entry were not. Redosing significantly reduced SSI incidence as shown by multivariate analysis (OR 0.60, 95% CI 0.37-0.96, p = 0.034), but exact timing had no significant impact. Long-duration surgery associates with higher SSI incidence. Irrespective of its exact timing, amp redosing significantly decreases SSI risk.

Sections du résumé

BACKGROUND
Long-duration surgery requires repeated administration of antimicrobial prophylaxis (amp). Amp "redosing" reduces incidence of surgical site infections (SSI) but is frequently omitted. Clinical relevance of redosing timing needs to be investigated. Here, we evaluated the effects of compliance with amp redosing and its timing on SSI incidence in prolonged duration surgery.
METHODS
Data from >9000 patients undergoing visceral, trauma, or vascular surgery with elective or emergency treatment in two tertiary referral Swiss hospitals were analyzed. All patients had to receive amp preoperatively and redosing, if indicated. Antibiotics used were cefuroxime (1.5 or 3 g, if weight >80 kg), or cefuroxime and metronidazole (1.5 and 0.5 g, or 3 and 1 g doses, if weight >80 kg). Alternatively, in cases of known or suspected allergies, vancomycin (1 g), gentamicin (4 mg/Kg), and metronidazole or clindamycin (300 mg) with or without ciprofloxacin (400 mg) were used. Association of defined parameters, including wound class, ASA scores, and duration of operation, with SSI incidence was explored.
RESULTS
In the whole cohort, SSI incidence significantly correlated with duration of surgery (ρ = 0.73, p = 0.031). In 593 patients undergoing >240 min long interventions, duration of surgery was the only parameter significantly (p < 0.001) associated with increased SSI risk, whereas wound class, ASA scores, treatment areas, and emergency versus elective hospital entry were not. Redosing significantly reduced SSI incidence as shown by multivariate analysis (OR 0.60, 95% CI 0.37-0.96, p = 0.034), but exact timing had no significant impact.
CONCLUSIONS
Long-duration surgery associates with higher SSI incidence. Irrespective of its exact timing, amp redosing significantly decreases SSI risk.

Identifiants

pubmed: 31292675
doi: 10.1007/s00268-019-05075-y
pii: 10.1007/s00268-019-05075-y
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2420-2425

Références

World J Surg. 2009 Jun;33(6):1165-73
pubmed: 19363694
Surg Infect (Larchmt). 2016 Apr;17(2):224-8
pubmed: 26719984
Transfusion. 2009 Sep;49(9):1964-70
pubmed: 19453989
Best Pract Res Clin Anaesthesiol. 2008 Sep;22(3):571-84
pubmed: 18831304
Medicine (Baltimore). 2017 Jul;96(29):e6903
pubmed: 28723736
Surg Infect (Larchmt). 2011 Aug;12(4):255-60
pubmed: 21790479
Emerg Infect Dis. 2001 Sep-Oct;7(5):828-31
pubmed: 11791504
Lancet Infect Dis. 2017 Jun;17(6):605-614
pubmed: 28385346
Infection. 2012 Apr;40(2):131-7
pubmed: 22002734
J Antimicrob Chemother. 2009 Dec;64(6):1307-15
pubmed: 19837713
Surg Today. 1999;29(12):1233-6
pubmed: 10639702
Surg Infect (Larchmt). 2017 May/Jun;18(4):474-484
pubmed: 27912036
Hosp Pharm. 2013 Jul;48(7):560-7
pubmed: 24421521
Lancet Infect Dis. 2016 Dec;16(12):e288-e303
pubmed: 27816414
Surg Infect (Larchmt). 2017 Aug/Sep;18(6):722-735
pubmed: 28832271
Am J Health Syst Pharm. 2013 Feb 1;70(3):195-283
pubmed: 23327981
J Am Coll Surg. 2013 Nov;217(5):770-9
pubmed: 24041563
Ann Surg. 2008 Jun;247(6):918-26
pubmed: 18520217
Ann Surg. 2009 Jul;250(1):10-6
pubmed: 19561486
Surgery. 2015 Aug;158(2):413-9
pubmed: 26054317
JAMA Surg. 2017 Aug 1;152(8):784-791
pubmed: 28467526
Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96
pubmed: 10196487
Surg Clin North Am. 2014 Dec;94(6):1245-64
pubmed: 25440122
Epidemiol Infect. 2011 Sep;139(9):1326-31
pubmed: 21087536
J Trauma Acute Care Surg. 2012 Aug;73(2):452-6; discussion 456
pubmed: 22846955
Int J Qual Health Care. 2016 Sep;28(4):502-7
pubmed: 27283440
Am Surg. 1997 Jan;63(1):59-62
pubmed: 8985073

Auteurs

Daniela Bertschi (D)

Department of Visceral Surgery, Kantonsspital Chur, Chur, Switzerland.

Walter P Weber (WP)

Department of General Surgery, University Hospital Basel, Basel, Switzerland.

Jasmin Zeindler (J)

Department of General Surgery, University Hospital Basel, Basel, Switzerland.

Daniel Stekhoven (D)

NEXUS Personalized Health Technologies, ETH Zurich, Zurich, Switzerland.

Robert Mechera (R)

Department of General Surgery, University Hospital Basel, Basel, Switzerland.

Lilian Salm (L)

Department of Visceral Surgery, Kantonsspital Aarau, Chirurgieaarau, Bahnhofstrasse 24, 5000, Aarau, Switzerland.

Marco Kralijevic (M)

Department of General Surgery, University Hospital Basel, Basel, Switzerland.

Savas D Soysal (SD)

Department of General Surgery, University Hospital Basel, Basel, Switzerland.

Marco von Strauss (M)

Department of Visceral Surgery, Kantonsspital Aarau, Chirurgieaarau, Bahnhofstrasse 24, 5000, Aarau, Switzerland.

Edin Mujagic (E)

Department of General Surgery, University Hospital Basel, Basel, Switzerland.

Walter R Marti (WR)

Department of Visceral Surgery, Kantonsspital Aarau, Chirurgieaarau, Bahnhofstrasse 24, 5000, Aarau, Switzerland. Walter.R.Marti@hin.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH